LONGITUDINAL EVALUATION OF SERUM ANDROGEN LEVELS IN MEN WITH AND WITHOUT PROSTATE-CANCER

被引:91
|
作者
CARTER, HB
PEARSON, JD
METTER, EJ
CHAN, DW
ANDRES, R
FOZARD, JL
ROSNER, W
WALSH, PC
机构
[1] JOHNS HOPKINS UNIV HOSP, SCH MED, JAMES BUCHANAN BRADY UROL INST, DEPT LAB MED, BALTIMORE, MD 21287 USA
[2] NIA, GERONTOL RES CTR, BALTIMORE, MD 21224 USA
[3] ROOSEVELT HOSP, DIV ENDOCRINOL, NEW YORK, NY USA
来源
PROSTATE | 1995年 / 27卷 / 01期
关键词
HORMONES; ANDROGENS; PROSTATE CANCER;
D O I
10.1002/pros.2990270106
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Androgens are thought to play a role in the pathogenesis of prostate cancer. We evaluated androgen levels in 3 age-matched groups of men who were part of the Baltimore Longitudinal Study of Aging: 1) 16 men with no prostatic disease by urologic history and exam (control group); 2) 20 men with a histologic diagnosis of benign prostatic hyperplasia (BPH) who had undergone simple prostatectomy; and 3) 20 men with a histologic diagnosis of prostate cancer (16 with local/regional cancer, and 4 with metastatic cancer). Luteinizing hormone (LH), total testosterone (T), and free T were measured on stored AM sera by radioimmunoassay (RIA). Free T was also calculated from the measured concentrations of total T and sex hormone binding globulin (SHBG). The median number of repeated sex steroid measurements ranged from 6-9 over a period from 7-25 years prior to the diagnosis of prostate disease. There were no significant differences in age-adjusted LH, total T, SHBG, or calculated free T levels among the groups at 0-5, 5-10, and 10-15 years before diagnosis. These data suggest that there are no measurable differences in serum testosterone levels among men who are destined to develop prostate cancer and those without the disease. (C) 1995 Wiley-Liss, Inc.
引用
收藏
页码:25 / 31
页数:7
相关论文
共 50 条
  • [31] ASSOCIATION BETWEEN SERUM ANDROGEN LEVELS AND PROSTATE CANCER: THE ROLE OF TESTOSTERONE IN THE PATHOGENESIS OF PROSTATE CANCER
    Imamoto, Takashi
    Utsumi, Takanobu
    Sazuka, Tomokazu
    Yanagisawa, Mitsuru
    Yano, Masashi
    Sakamoto, Shinichi
    Kawamura, Koji
    Kamiya, Naoto
    Nihei, Naoki
    Suzuki, Hiroyoshi
    Ichikawa, Tomohiko
    JOURNAL OF SEXUAL MEDICINE, 2013, 10 : 206 - 206
  • [32] NEW FORMS OF ANDROGEN DEPRIVATION FOR TREATMENT OF PROSTATE-CANCER
    SOLOWAY, MS
    SOUTHERN MEDICAL JOURNAL, 1986, 79 (09) : 79 - 79
  • [33] ANDROGEN PRIMING AND RESPONSE TO CHEMOTHERAPY IN ADVANCED PROSTATE-CANCER
    SANTEN, R
    MANNI, A
    BOUCHER, A
    LIPTON, A
    HARVEY, H
    WHITE, D
    SIMMONDS, M
    GORDON, R
    ROHNER, T
    DRAGO, J
    WETTLAUFER, J
    GLODE, L
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1986, 22 (06): : 729 - 729
  • [34] COMPLETE ANDROGEN BLOCKADE IN PROSTATE-CANCER - ORGANIZING AN OVERVIEW
    DALESIO, O
    CANCER, 1990, 66 (05) : 1080 - 1082
  • [35] ANDROGEN SUPPRESSION BY KETOCONAZOLE IN PATIENTS WITH METASTATIC PROSTATE-CANCER
    DECKER, DA
    SUBRAMANIAN, M
    SINGHAKOWINTA, A
    BREAST CANCER RESEARCH AND TREATMENT, 1983, 3 (03) : 315 - 315
  • [36] ROLE OF MAXIMAL ANDROGEN BLOCKADE IN ADVANCED PROSTATE-CANCER
    DENIS, L
    PROSTATE, 1994, : 17 - 22
  • [37] MUTATED ANDROGEN RECEPTORS OF PROSTATE-CANCER CELLS - REPLY
    BALK, SP
    BUBLEY, GJ
    SHUSTER, TD
    NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (15): : 1010 - 1011
  • [38] RATE OF CHANGE IN SERUM PROSTATE-SPECIFIC ANTIGEN LEVELS AS A METHOD FOR PROSTATE-CANCER DETECTION
    SMITH, DS
    CATALONA, WJ
    JOURNAL OF UROLOGY, 1994, 152 (04): : 1163 - 1167
  • [39] GNRH SUPERAGONIST ANALOG TREATMENT OF PROSTATE-CANCER - HORMONAL EFFECTS WITH AND WITHOUT AN ANDROGEN BIOSYNTHESIS INHIBITOR
    SANTEN, R
    ENGLISH, H
    WARNER, B
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1984, 20 (6B): : 1375 - 1375
  • [40] EFFECTS OF AGE, SEX STEROIDS, AND FAMILY RELATIONSHIPS ON VOLUMES OF PROSTATE ZONES IN MEN WITH AND WITHOUT PROSTATE-CANCER
    MEIKLE, AW
    STEPHENSON, RA
    MCWHORTER, WP
    SKOLNICK, MH
    MIDDLETON, RG
    PROSTATE, 1995, 26 (05): : 253 - 259